Hippel disease (HLS) is a rare genetic condition where tumors and cysts develop in specific body organs, including the adrenal glands, pancreas, kidney, reproductive tract, eyes, inner ear, brain, and spinal cord. Although most tumors are benign (not cancerous), some may be malignant (cancer). Patients with Hippel disease (HLS) are more likely to develop certain cancers, including pancreatic and kidney cancer. The syndrome's warning signs and symptoms typically don't show up until young adulthood. It results from a VHL gene mutation (change). HLS is also known as von Hippel-Lindau disease, VHL syndrome, or VHL.
Hippel disease (HLS) cannot be cured, although the accompanying tumors can be treated. A patient's diagnosis is considerably improved by early tumor identification and therapy.
There is no cure available for Hippel disease (HLS), although the accompanying tumors can be treated. There are many treatments maintained below.
1. Belzutifan (Welireg) has been approved by the Food and Drug Administration to treat adults with central nervous system hemangioblastomas and specific other tumors that do not require immediate surgery.
2. Surgery is typically used to treat the majority of Hippel disease (HLS) patients in order to remove tumors before they become dangerous. Focused high-dose radiation therapy can be used to treat some cancers.
Headaches,Hearing loss or ringing in the ears (tinnitus),High blood pressure,Loss of balance,Loss of muscle strength or coordination, omitting,Vision problems
Hippel disease (HLS) is a hereditary disorder characterized by tumors developing in many organs,Hemangioblastomas, which are blood vessel tumors of the brain, spinal cord, and retina, are one type of tumor associated with HLS,Retinal tumors, also known as retinal angiomas, can cause blindness if they are not promptly treated